A new molecular scoring system promises to improve the treatment of a set of blood cancers called myelodysplastic syndromes (MDS), according to an international team of researchers. The findings were ...
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data. An abstract and poster presented at the 2023 American ...
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk ...
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020. Hematologic and transfusion outcomes ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ...
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs). Patients with myelodysplastic ...
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found. Allogeneic hematopoietic cell transplantation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback